Josep Tabernero MD, PhD’s Post

15 February marks International #ChildhoodCancer Day, providing an opportunity to raise awareness and emphasize the importance of supporting research to give all children with cancer the best chance to live their dreams. Thanks to advances in cancer care, 80% of children now survive 5 years or more, but we know that more can be done. At Servier, we are committed to fighting against cancer and becoming an innovative player focused on hard-to-treat cancers, such as pediatric cancers. Each year, we invest over 70% of our 🔬 R&D budget in oncology. #oncology #cancer #childhoodcancer #pediatriccancer #ICCD2024 #WeWontRest #cancersurvivor #researchanddevelopment #clinicaltrials #patientadvocacy #mission ACCELERATE Multi-Stakeholder Platform MIB Agents Osteosarcoma Alliance

Our team is looking forward to connecting with leading clinicians and researchers and to discussing the latest progress in #GIcancer at the ESMO - European Society for Medical Oncology Gastrointestinal Cancers Congress. Ulixertinib, our highly selective, first-in-class ERK 1/2 inhibitor, is being evaluated in combination with hydroxychloroquine in individuals with advanced gastrointestinal malignancies, including cholangiocarcinoma, pancreatic adenocarcinoma, colorectal adenocarcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma. Learn more about the study: https://lnkd.in/eNbpDbJW #ESMOGI24 #MAPK

Follow our Journey with BupiZenge targeting Oral mucositis pain!

Exploring the feasibility, safety and early survival outcomes of HIPEC in addition to interval CRS for two unaddressed sub-groups ⏩ stage IV disease ⏩ >4 cycles of NACT Open access https://lnkd.in/djTzbSF8 Encouraging PFS for these 'difficult' and unaddressed subgroups European Society of Surgical Oncology (ESSO) American Society of Clinical Oncology (ASCO) #HIPEC #OVARIANCANCER #INTERVALCYTOREDUCTIVESURGERY #INTERVALDEBULKING

Finding from the phase 3 ARMANI trial (NCT02934464) were presented by Dr. Giovanni Randon at the European Society for Medical Oncology Gastrointestinal Cancers Congress 2024📊🔬, showing that switch maintenance therapy using paclitaxel and ramucirumab significantly extends survival in patients with HER2-negative, metastatic gastric cancer, irrespective of clinical or molecular subgroups. 🌟Check out our latest coverage and stay tuned for more insights on these groundbreaking results! #MetastaticGastricCancer #Paclitaxel #Ramucirumab #Taxol #Cyramza #ARMANItrial #ESMO2024 #CancerResearch #OncologyNews https://lnkd.in/ePhKUNWF

First special article collection on treating GI cancers in resource-restricted countries: Gastrointestinal Oncology: Management and Care: Treating GI cancers in resource-restricted countries . Calling all healthcare professionals, researchers, and experts in gastrointestinal oncology! Taylor and Francis proudly presents the First Special Article Collection on "Gastrointestinal Oncology: Management and Care - Treating GI Cancers in Resource-Restricted Countries." Under the guidance of Prof Janusz Jankowski . Don't miss this opportunity to contribute to and learn from the latest advancements in gastrointestinal oncology, with a focus on improving outcomes where resources are limited. Submit your research or explore groundbreaking articles today! Visit the link below to access this groundbreaking collection: https://lnkd.in/d5wvDwFy #GIoncology #ResourceRestrictedCountries #TaylorandFrancis #Healthcare #Research #GastrointestinalCancers #MakeADifference

Sometimes its the simple things that can make a difference in patient experience. We are so excited that we have the ability to give subcutaneous trastuzumab (Herceptin)/pertuzumab (Perjeta) instead of IV in our #Nashville practice SCRI Oncology Partners. Article out today in JCO Oncology Practice about the impacts of sub-q administration vs. IV administration of these #HER2 agents. Spoiler alert ⚠: SQ trastuzumab/pertuzumab translated to over 1 hour less ⏰ chair time for patients at EACH administration. Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial) | JCO Oncology Practice (ascopubs.org)

I want to thank patients, investigators and their staff for participating in our clinical trial with monotherapy #roginolisib, which was presented by #AnnaMariaDiGiacomo at this year´s Annual Meeting of the American Society of Clinical Oncology (#ASCO2024) in Chicago (see https://lnkd.in/dFpfc_cX; also see: ASCO® 2024 Insights: "Roginolisib, an Oral, Highly Selective and Allosteric Modulator of PI3Kd for Uveal Melanoma and Advanced Cancers" | VuMedi).  We are excited to learn more about the activity of roginolisib in patients with metastatic uveal melanoma as we continue to analyze the biomarker data from patients treated with #roginolisib. Such data will be presented at future medical conferences.

Starting today, oncologists worldwide can access comprehensive insights and valuable information about triple-negative breast cancer on Oncology Compass. Recent publications, congress news and study summaries - all data is now available on the platform. It took the combined efforts of a team of experts to build a library of selected key publications.  Prof.Dr. Jens Huober joined the Oncology Compass team and will serve as the Scientific Leader on the triple-negative breast cancer indication. He currently serves as the Chief Physician at the Breast Center St.Gallen and is a member of the Steering Committee at the Comprehensive Cancer Centre. He is a specialist in gynecology and obstetrics, with a particular focus on senology and the systemic therapy of breast and gynecological malignancies. Thirty nine highly relevant publications, with many more to follow, can quickly be searched by clinical characteristics. This time-efficient research helps oncologists to get updates in a time-efficient manner. With the addition of this cancer type to the existing information, HCPs now have the tool to filter the most relevant information about the newest practices in treating triple-negative breast cancer, all in one place. Register to access Oncology Compass today: https://lnkd.in/dUADmZp2 #TripleNegativeBreastCancer #TNBC #BreastCancer #Oncology #OncologyCompass

The current treatment landscape for OM is characterised by lack of standardized, effective, well-tolerated and safe options. In particular the pain associated with OM continues to represent a significant unmet medical need as it affects patients on multiple levels, including impaired psychological and physical quality of life, and adverse effects on their cancer treatment and hence, potentially, survival. We aim to adress this unmet need. #Oralmucositis #Cancer #Headandneckcancer #HNcancerawarenessmonth #Oralpain #REDUCEOPIOIDUSE Follow our Journey below.